What is behind Moderna recent gain in value today

Traders Union
All News
Financial News
Moderna rises 2.57% to $51.58 today

Highlights

The FDA agreed to review Moderna's biologics license application for its seasonal mRNA flu vaccine after resolving prior concerns, marking a key regulatory milestone.
Moderna reported better-than-expected quarterly earnings and is progressing with regulatory approvals in Europe and Canada for its combination flu and COVID vaccine.
MRNA trades above the MA-20 ($44.31), MA-50 ($38.86), and MA-200 ($29.88) with resistance at $55 and strong bullish momentum confirmed by MACD and ADX.

FDA review and global partnerships lift sentiment and earnings outlook

The U.S. Food and Drug Administration has agreed to review Moderna's biologics license application for its seasonal mRNA flu vaccine, following the company's successful resolution of previous concerns. Additional drivers include regulatory progress in Europe and Canada for a combination flu and COVID vaccine, anticipated data for a norovirus vaccine, and better-than-expected quarterly earnings. Moderna is also expanding global production and entering new strategic partnerships with other pharmaceutical firms.

Anton Kharitonov, expert at Traders Union, sees Moderna's surge above key moving averages as technically impressive but cautions against complacency. He notes the rally is largely news-driven, reflecting regulatory headlines and upbeat earnings. However, overbought conditions across RSI, Stoch RSI, and CCI raise red flags for short-term sustainability. Kharitonov warns that sentiment could quickly reverse if momentum cools, especially with the price stretched far above support. "With oscillators this overextended and the move fueled by event risk, I advise traders to protect capital and avoid chasing at these levels."

Viktoras Karapetjanc, expert at Traders Union, views the setup as structurally bullish with strong fundamental backing. Regulatory advances across the US, Europe, and Canada enhance the company’s growth trajectory. The bullish trend is reinforced by solid earnings and new strategic partnerships. Karapetjanc believes the market offers attractive setups as global expansion continues. "With catalysts piling up and momentum in place, I expect further growth and see the bullish structure as firmly intact for Moderna."

Parshwa Turakhiya, analyst, notes short-term sentiment is extremely positive, driven by strong news flow and a dominant buying impulse. Technically, momentum remains robust, yet indicators signal very stretched conditions that often precede a pause or quick retracement. He highlights an immediate opportunity driven by volatility, with a watchful eye on support near $45.93. "Bulls control the current setup, but for tactical entries, I’d wait for a short-term reset or pullback before jumping in."

Bullish momentum endures amid overbought signals and strong resistance

MRNA trades firmly above the MA-20 at $44.31, MA-50 at $38.86, and MA-200 at $29.88, confirming robust bullish momentum for short-, medium-, and long-term trends. The next dynamic support lies near the Ichimoku Kijun at $45.93, while resistance is seen at $55, the next round level above the current price. Momentum remains strong, with bullish signals from both MACD and ADX. However, overbought readings from the RSI (69.34), Stoch RSI (100), CCI (160.11), and BBP suggest frothy conditions, with buyers clearly dominating in the short term. The Awesome Oscillator also confirms upward momentum. There was no notable gap at today’s open, and the price is holding near the top of today’s range after a 2.57% gain, reflecting high volatility and persistent strength toward session highs. Despite the overbought warnings, intraday performance aligns with the momentum indicators, though traders should watch for a near-term pause or minor pullback given the stretched oscillator readings.

Last time, analysts noted that Moderna maintains a firmly bullish short- and long-term structure, trading well above key moving averages with strong momentum confirmed by MACD, ADX, and a persistent upside in RSI near overbought levels. While dynamic support is established near $45.93 and resistance appears close to recent intraday highs, intensified overbought signals suggest elevated risk of near-term pullbacks despite prevailing buying pressure.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.